

Eltrombopag Olamine (PROMACTA) Tablets and Powder for Oral Suspension and Eltrombopag Choline (ALVAIZ) Tablets in Immune Thrombocytopenia (ITP) Criteria for Use April 2024

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive eltrombopag.

- Stem cell disorder (i.e., myelodysplastic syndrome)
- Patient has not received prior therapy, with steroids, to increase platelet counts
- Thrombocytopenia is secondary to bone marrow suppressive anti-cancer therapy, antibiotics or other drugs¹
- Thromboembolic events within the past year, unless evaluated by a hematology provider and deemed to be an appropriate candidate
- Pregnancy and/or lactating

Inclusion Criteria

All of the following criteria must be met.

- Diagnosis of chronic immune thrombocytopenia (ITP)
- Platelet count less than 30,000 mm³ and/or persistent bleeding resistant / refractory to glucocorticoids
- Patient has relapse after the following second-line therapies (unless contraindicated or patient is not a candidate): Splenectomy and rituximab

Additional Inclusion Criteria

- For patients who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy

Other Justification

Footnotes

- 1 For thrombocytopenia due to chronic liver disease, refer to separate criteria for use for avatrombopag and lusutrombopag.

Prepared: April 2024 by Francine Goodman, PharmD, BCPS, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services – Formulary Management (12PBM)

Contact: Bernadette Heron, PharmD, BCOP, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services – Formulary Management (12PBM)
